Gast ::
| Hauptseite > Publikationsdatenbank > The strategic biomarker roadmap for the validation of Alzheimer’s diagnostic biomarkers: methodological update > print |
| Hauptseite > Publikationsdatenbank > The strategic biomarker roadmap for the validation of Alzheimer’s diagnostic biomarkers: methodological update > print |
| 001 | 904297 | ||
| 005 | 20230123101902.0 | ||
| 024 | 7 | _ | |a 10.1007/s00259-021-05549-z |2 doi |
| 024 | 7 | _ | |a 0340-6997 |2 ISSN |
| 024 | 7 | _ | |a 1432-105X |2 ISSN |
| 024 | 7 | _ | |a 1619-7070 |2 ISSN |
| 024 | 7 | _ | |a 1619-7089 |2 ISSN |
| 024 | 7 | _ | |a 2128/32287 |2 Handle |
| 024 | 7 | _ | |a 34546388 |2 pmid |
| 024 | 7 | _ | |a WOS:000698040800001 |2 WOS |
| 037 | _ | _ | |a FZJ-2021-05867 |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Boccardi, Marina |0 P:(DE-HGF)0 |b 0 |e Corresponding author |
| 245 | _ | _ | |a The strategic biomarker roadmap for the validation of Alzheimer’s diagnostic biomarkers: methodological update |
| 260 | _ | _ | |a Heidelberg [u.a.] |c 2021 |b Springer-Verl. |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1667393960_26491 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Background: The 2017 Alzheimer's disease (AD) Strategic Biomarker Roadmap (SBR) structured the validation of AD diagnostic biomarkers into 5 phases, systematically assessing analytical validity (Phases 1-2), clinical validity (Phases 3-4), and clinical utility (Phase 5) through primary and secondary Aims. This framework allows to map knowledge gaps and research priorities, accelerating the route towards clinical implementation. Within an initiative aimed to assess the development of biomarkers of tau pathology, we revised this methodology consistently with progress in AD research.Methods: We critically appraised the adequacy of the 2017 Biomarker Roadmap within current diagnostic frameworks, discussed updates at a workshop convening the Alzheimer's Association and 8 leading AD biomarker research groups, and detailed the methods to allow consistent assessment of aims achievement for tau and other AD diagnostic biomarkers.Results: The 2020 update applies to all AD diagnostic biomarkers. In Phases 2-3, we admitted a greater variety of study designs (e.g., cross-sectional in addition to longitudinal) and reference standards (e.g., biomarker confirmation in addition to clinical progression) based on construct (in addition to criterion) validity. We structured a systematic data extraction to enable transparent and formal evidence assessment procedures. Finally, we have clarified issues that need to be addressed to generate data eligible to evidence-to-decision procedures.Discussion: This revision allows for more versatile and precise assessment of existing evidence, keeps up with theoretical developments, and helps clinical researchers in producing evidence suitable for evidence-to-decision procedures. Compliance with this methodology is essential to implement AD biomarkers efficiently in clinical research and diagnostics.Keywords: Alzheimer’s disease; Biomarker; Dementia; MCI; Mild cognitive impairment; Validation methodology. |
| 536 | _ | _ | |a 5253 - Neuroimaging (POF4-525) |0 G:(DE-HGF)POF4-5253 |c POF4-525 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, Journals: juser.fz-juelich.de |
| 700 | 1 | _ | |a Dodich, Alessandra |0 P:(DE-HGF)0 |b 1 |
| 700 | 1 | _ | |a Albanese, Emiliano |0 P:(DE-HGF)0 |b 2 |
| 700 | 1 | _ | |a Gayet-Ageron, Angèle |0 P:(DE-HGF)0 |b 3 |
| 700 | 1 | _ | |a Festari, Cristina |0 P:(DE-HGF)0 |b 4 |
| 700 | 1 | _ | |a Ashton, Nicholas J. |0 P:(DE-HGF)0 |b 5 |
| 700 | 1 | _ | |a Bischof, Gérard N. |0 P:(DE-HGF)0 |b 6 |
| 700 | 1 | _ | |a Chiotis, Konstantinos |0 P:(DE-HGF)0 |b 7 |
| 700 | 1 | _ | |a Leuzy, Antoine |0 P:(DE-HGF)0 |b 8 |
| 700 | 1 | _ | |a Wolters, Emma E. |0 P:(DE-HGF)0 |b 9 |
| 700 | 1 | _ | |a Walter, Martin |0 P:(DE-HGF)0 |b 10 |
| 700 | 1 | _ | |a Rabinovici, Gil D. |0 P:(DE-HGF)0 |b 11 |
| 700 | 1 | _ | |a Carrillo, Maria |0 P:(DE-HGF)0 |b 12 |
| 700 | 1 | _ | |a Drzezga, Alexander |0 P:(DE-Juel1)177611 |b 13 |
| 700 | 1 | _ | |a Hansson, Oskar |0 P:(DE-HGF)0 |b 14 |
| 700 | 1 | _ | |a Nordberg, Agneta |0 P:(DE-HGF)0 |b 15 |
| 700 | 1 | _ | |a Ossenkoppele, Rik |0 P:(DE-HGF)0 |b 16 |
| 700 | 1 | _ | |a Villemagne, Victor L. |0 P:(DE-HGF)0 |b 17 |
| 700 | 1 | _ | |a Winblad, Bengt |0 P:(DE-HGF)0 |b 18 |
| 700 | 1 | _ | |a Frisoni, Giovanni |0 P:(DE-HGF)0 |b 19 |
| 700 | 1 | _ | |a Garibotto, Valentina |0 P:(DE-HGF)0 |b 20 |
| 773 | _ | _ | |a 10.1007/s00259-021-05549-z |g Vol. 48, no. 13, p. 4525 - 4531 |0 PERI:(DE-600)2098375-X |n 13 |p 4525 - 4531 |t European journal of nuclear medicine and molecular imaging |v 48 |y 2021 |x 0340-6997 |
| 856 | 4 | _ | |u https://juser.fz-juelich.de/record/904297/files/The%20strategic%20biomarker%20roadmap_fulltext.pdf |y OpenAccess |
| 909 | C | O | |o oai:juser.fz-juelich.de:904297 |p openaire |p open_access |p VDB |p driver |p dnbdelivery |
| 910 | 1 | _ | |a German Center for Neurodegenerative Diseases DZNE-Standort Rostock/Greifswald, Gehlsheimer Str. 20, 18147, Rostock, Germany. marina.boccardi@dzne.de. |0 I:(DE-HGF)0 |b 0 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a LANVIE - Laboratory of Neuroimaging of Aging, University of Geneva, Geneva, Switzerland. marina.boccardi@dzne.de |0 I:(DE-HGF)0 |b 0 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Center for Neurocognitive Rehabilitation (CeRiN), CIMeC, University of Trento, Trento, Italy |0 I:(DE-HGF)0 |b 1 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a NIMTlab - Neuroimaging and Innovative Molecular Tracers Laboratory, University of Geneva, Geneva, Switzerland |0 I:(DE-HGF)0 |b 1 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a USI - Università della Svizzera Italiana, Institute of Public Health (IPH), Lugano, Switzerland |0 I:(DE-HGF)0 |b 2 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Division of Clinical Epidemiology, Department of Health and Community Medicine, University of Geneva & University Hospitals of Geneva, Geneva, Switzerland |0 I:(DE-HGF)0 |b 3 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a LANE - Laboratory of Alzheimer's Neuroimaging and Epidemiology, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy |0 I:(DE-HGF)0 |b 4 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden |0 I:(DE-HGF)0 |b 5 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Department of Psychiatry and Neurochemistry, Institute of Neuroscience & Physiology, The Sahlgrenska Academy at The University of Gothenburg, Molndal, Sweden |0 I:(DE-HGF)0 |b 5 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation, London, UK |0 I:(DE-HGF)0 |b 5 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK |0 I:(DE-HGF)0 |b 5 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Department of Nuclear Medicine, University Hospital Cologne, Cologne, Germany |0 I:(DE-HGF)0 |b 6 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Division of Clinical Geriatrics, Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden |0 I:(DE-HGF)0 |b 7 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Theme Neurology, Karolinska University Hospital, Stockholm, Sweden |0 I:(DE-HGF)0 |b 7 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Division of Clinical Geriatrics, Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden |0 I:(DE-HGF)0 |b 8 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, Netherlands |0 I:(DE-HGF)0 |b 9 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Nuclear Medicine and Molecular Division, Geneva Medical Hospital, Geneva, Switzerland |0 I:(DE-HGF)0 |b 10 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Departments of Neurology, Radiology & Biomedical Imaging, University of California, San Francisco, CA, USA |0 I:(DE-HGF)0 |b 11 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Alzheimer's Association, Chicago, IL, USA |0 I:(DE-HGF)0 |b 12 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 13 |6 P:(DE-Juel1)177611 |
| 910 | 1 | _ | |a Faculty of Medicine, University of Cologne, Cologne, Germany |0 I:(DE-HGF)0 |b 13 |6 P:(DE-Juel1)177611 |
| 910 | 1 | _ | |a German Center for Neurodegenerative Diseases (DZNE), Bonn/Cologne, Germany |0 I:(DE-HGF)0 |b 13 |6 P:(DE-Juel1)177611 |
| 910 | 1 | _ | |a Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Lund, Sweden |0 I:(DE-HGF)0 |b 14 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Memory Clinic, Skåne University Hospital, Malmo, Sweden |0 I:(DE-HGF)0 |b 14 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Division of Clinical Geriatrics, Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden |0 I:(DE-HGF)0 |b 15 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Karolinska University Hospital, Theme Aging, Geriatric Clinic, Huddinge, Sweden |0 I:(DE-HGF)0 |b 15 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, Netherlands |0 I:(DE-HGF)0 |b 16 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Department of Clinical Memory Research, Lund University, Lund, Sweden |0 I:(DE-HGF)0 |b 16 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Department of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsilvania, USA |0 I:(DE-HGF)0 |b 17 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Department of Neurobiology, Care Sciences and Society, Division of Neurogeriatrics, Karolinska Institutet, Stockholm, Sweden |0 I:(DE-HGF)0 |b 17 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Karolinska University Hospital, Theme Aging, Geriatric Clinic, Huddinge, Sweden |0 I:(DE-HGF)0 |b 18 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Department of Neurobiology, Care Sciences and Society, Division of Neurogeriatrics, Karolinska Institutet, Stockholm, Sweden |0 I:(DE-HGF)0 |b 18 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a LANVIE - Laboratory of Neuroimaging of Aging, University of Geneva, Geneva, Switzerland |0 I:(DE-HGF)0 |b 19 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Memory Clinic, University Hospital, Geneva, Switzerland |0 I:(DE-HGF)0 |b 19 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a USI - Università della Svizzera Italiana, Institute of Public Health (IPH), Lugano, Switzerland |0 I:(DE-HGF)0 |b 20 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Nuclear Medicine and Molecular Division, Geneva Medical Hospital, Geneva, Switzerland |0 I:(DE-HGF)0 |b 20 |6 P:(DE-HGF)0 |
| 913 | 1 | _ | |a DE-HGF |b Key Technologies |l Natural, Artificial and Cognitive Information Processing |1 G:(DE-HGF)POF4-520 |0 G:(DE-HGF)POF4-525 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-500 |4 G:(DE-HGF)POF |v Decoding Brain Organization and Dysfunction |9 G:(DE-HGF)POF4-5253 |x 0 |
| 914 | 1 | _ | |y 2022 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2021-02-02 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2021-02-02 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2021-02-02 |
| 915 | _ | _ | |a Creative Commons Attribution CC BY 4.0 |0 LIC:(DE-HGF)CCBY4 |2 HGFVOC |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2021-02-02 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b EUR J NUCL MED MOL I : 2019 |d 2021-02-02 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2021-02-02 |
| 915 | _ | _ | |a DEAL Springer |0 StatID:(DE-HGF)3002 |2 StatID |d 2021-02-02 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2021-02-02 |
| 915 | _ | _ | |a OpenAccess |0 StatID:(DE-HGF)0510 |2 StatID |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2021-02-02 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b EUR J NUCL MED MOL I : 2019 |d 2021-02-02 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2021-02-02 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2021-02-02 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2021-02-02 |
| 920 | _ | _ | |l yes |
| 920 | 1 | _ | |0 I:(DE-Juel1)INM-2-20090406 |k INM-2 |l Molekulare Organisation des Gehirns |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a I:(DE-Juel1)INM-2-20090406 |
| 980 | 1 | _ | |a FullTexts |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|